Search Results - "MATAR, Pablo"

Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment by Croci, Diego O, Zacarías Fluck, Mariano F, Rico, María J, Matar, Pablo, Rabinovich, Gabriel A, Scharovsky, O Graciela

“…Accumulating evidence indicates that a dynamic cross-talk between tumors and the immune system can regulate tumor growth and metastasis. Increased…”
Get full text

ZD1839, a Specific Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Induces the Formation of Inactive EGFR/HER2 and EGFR/HER3 Heterodimers and Prevents Heregulin Signaling in HER2-overexpressing Breast Cancer Cells by ANIDO, Judit, MATAR, Pablo, ALBANELL, Joan, GUZMAN, Marta, ROJO, Federico, ARRIBAS, Joaquin, AVERBUCH, Steve, BASELGA, Jose

“…Purpose: ZD1839 is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) that has shown clinical activity against EGFR-expressing tumors…”
Get full text

Efecto bimodal de la ciclofosfamida en la terapia antineoplásica by Matar, Pablo, Scharovsky, O. Graciela

“…La Ciclofosfamida (Cy) es el agente alquilante más utilizado en el tratamento quimioterápico de diversas neoplasias humanas; habitualmente se la administra em…”
Get full text

A Novel Synergistic Combination of Cyclophosphamide and Gene Transfer of Interleukin-12 Eradicates Colorectal Carcinoma in Mice by MALVICINI, Mariana, RIZZO, Miguel, MAZZOLINI, Guillermo, ALANIZ, Laura, PINERO, Federico, GARCIA, Mariana, ATORRASAGASTI, Catalina, AQUINO, Jorge B, ROZADOS, Viviana, GRACIELA SCHAROVSKY, O, MATAR, Pablo

“…Purpose: Interleukin-12 (IL-12) is an immunostimulatory cytokine with potent antitumor effects in several animal models. However, serious toxicity has been…”
Get full text

Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice by Malvicini, Mariana, Alaniz, Laura, Bayo, Juan, Garcia, Mariana, Piccioni, Flavia, Fiore, Esteban, Atorrasagasti, Catalina, Aquino, Jorge B., Matar, Pablo, Mazzolini, Guillermo

“…The use of conventional cytotoxic agents at metronomic schedules, alone or in combination with targeted agents or immunotherapy, is being explored as a…”
Get full text

Immunotherapy for liver tumors: present status and future prospects by Matar, Pablo, Alaniz, Laura, Rozados, Viviana, Aquino, Jorge B, Malvicini, Mariana, Atorrasagasti, Catalina, Gidekel, Manuel, Silva, Marcelo, Scharovsky, O Graciela, Mazzolini, Guillermo

“…Increasing evidence suggests that immune responses are involved in the control of cancer and that the immune system can be manipulated in different ways to…”
Get full text

Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model by MATAR, Pablo, ROZADOS, Viviana R, GERVASONI, Silvia I, SCHAROVSKY, O. Graciela

“…Cyclophosphamide (Cy) is an alkylating agent widely used in cancer chemotherapy. It has a bimodal effect on the immune system, depending on the dose and…”
Get full text

Chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide by Malvicini, Mariana, Piccioni, Flavia, Bayo, Juan, Fiore, Esteban, Atorrasagasti, Catalina, Alaniz, Laura, Garcia, Mariana, Aquino, Jorge B., Gidekel, Manuel, Matar, Pablo, Mazzolini, Guillermo

“…The combination of a single low dose of cyclophosphamide (Cy) with the adenovirus-mediated gene transfer of interleukin-12 (AdIL-12) might represent a…”
Get full text

Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225) by Pablo Matar, Federico Rojo, Raúl Cassia, Gema Moreno-Bueno, Serena Di Cosimo, José Tabernero, Marta Guzmán, Sonia Rodriguez, Joaquín Arribas, José Palacios, José Baselga

“…Purpose: The epidermal growth factor receptor (EGFR) is abnormally activated in cancer and two classes of anti-EGFR agents, monoclonal antibodies and…”
Get full text

Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma by Malvicini, Mariana, Fiore, Esteban, Ghiaccio, Valentina, Piccioni, Flavia, Rizzo, Miguel, Olmedo Bonadeo, Lucila, García, Mariana, Rodríguez, Marcelo, Bayo, Juan, Peixoto, Estanislao, Atorrasagasti, Catalina, Alaniz, Laura, Aquino, Jorge, Matar, Pablo, Mazzolini, Guillermo

“…We have previously demonstrated that a low dose of cyclophosphamide (Cy) combined with gene therapy of interleukin-12 (AdIL-12) has a synergistic, although…”
Get full text

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting by MATAR, Pablo, ROJO, Federico, BASELGA, José, CASSIA, Raul, MORENO-BUENO, Gema, DI COSIMO, Serena, TABERNERO, José, GUZMAN, Marta, RODRIGUEZ, Sonia, ARRIBAS, Joaquin, PALACIOS, José

“…The epidermal growth factor receptor (EGFR) is abnormally activated in cancer and two classes of anti-EGFR agents, monoclonal antibodies and…”
Get full text

Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response by Alaniz, Laura, Rizzo, Miguel, Malvicini, Mariana, Jaunarena, Jorge, Avella, Diego, Atorrasagasti, Catalina, Aquino, Jorge B, Garcia, Mariana, Matar, Pablo, Silva, Marcelo, Mazzolini, Guilermo

“…Abstract Hyaluronan modulates cancer progression by multiple mechanisms; nevertheless, its effects remain controversial. In this work, low molecular weight…”
Get full text

Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12 by Malvicini, Mariana, Ingolotti, Mariana, Piccioni, Flavia, Garcia, Mariana, Bayo, Juan, Atorrasagasti, Catalina, Alaniz, Laura, Aquino, Jorge B., Espinoza, Jaime A., Gidekel, Manuel, Scharovsky, O. Graciela, Matar, Pablo, Mazzolini, Guillermo

“…Immunotherapy-based strategies for gastrointestinal carcinomas (GIC) have been exploited so far, but these approaches have to face strong mechanisms of immune…”
Get full text

Cancer immunotherapy. Importance of overcoming immune suppression by Malvicini, Mariana, Puchulo, Guillermo, Matar, Pablo, Mazzolini, Guillermo

“…Increasing evidence indicates that the immune system is involved in the control of tumor progression. Effective antitumor immune response depends on the…”
Get full text

The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide by Rozados, Viviana R, Mainetti, Leandro E, Rico, María J, Zacarías Fluck, Mariano F, Matar, Pablo, Scharovsky, O Graciela

“…Metronomic chemotherapy (MCT) is a novel therapeutic strategy for cancer treatment endowed with an antiangiogenic effect. It refers to regular administration…”
Get more information

Modulation of IL-10/IL-10R expression by mafosfamide, a derivative of 4-hydroxycyclophosphamide, in a rat B-cell lymphoma by Rico, Maria J, Matar, Pablo, Scharovsky, O Graciela

“…We have already shown that IL-10 plays an important role in immunosuppression and metastatic dissemination in the rat B-cell lymphoma L-TACB model. It was…”
Get full text

Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models by ROZADOS, Viviana R, HINRICHSEN, Lucila I, BINDA, M. Mercedes, GERVASONI, Silvia I, MATAR, Pablo, BONFIL, R. Daniel, SCHAROVSKY, O. Graciela

“…Despite its effectiveness as an antineoplastic drug, doxorubicin (DOX) is usually associated with cardiotoxicity. Lovastatin (LOV), a hypolipidemic agent used…”
Get full text

Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research by Scharovsky, O Graciela, Matar, Pablo, Rozados, Viviana R, Rico, María J, Zacarías Fluck, Mariano F, Mainetti, Leandro E, Fernández Zenóbi, M Virginia, Roggero, Eduardo A, Gervasoni, Silvia I, Rossa, Ana, Perroud, Hernán A, Sánchez, Andrea M, Celoria, Guillermo C, Font, María T

“…Basic and pre-clinic research in cellular and molecular oncology are the main supports accounting for the advancement in cancer therapeutics. The findings…”
Get full text

Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin by Ciocca, Daniel R., Rozados, Viviana R., Cuello Carrión, F. Darío, Gervasoni, Silvia I., Matar, Pablo, Scharovsky, O. Graciela

“…Heat shock protein 27 (Hsp27) and Hsp70 have been involved in resistance to anticancer drugs in human breast cancer cells growing in vitro and in vivo. In this…”
Get full text

Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response by Matar, Pablo, Rozados, Viviana R, Gervasoni, Silvia I, Scharovsky, O.Graciela

“…In previous reports, we demonstrated an inhibitory effect of a single low-dose of cyclophosphamide (Cy) on spontaneous and experimental metastasis of a rat…”
Get full text